MSTN and sarcopenia: Of note, the larger muscle mass in myostatin KOs does not translate into increased strength (Amthor et al., 2007), which might in part explain why pharmacological inhibition of myostatin signaling largely failed to mitigate functional impairments in muscle wasting diseases and sarcopenia (Rooks et al., 2020).